October 28-29, 2024 | Boston, MA

Identifying and Advancing Novel Pain Drugs Through Preclinical, Clinical Development and Commercialization

Press Releases

August 1, 2016

Research on an fMRI-Based Neurologic Signature of Physical Pain to be Presented at Upcoming 10th Annual Pain & Migraine Therapeutics Summit
As persistent pain is solely measured by self-report, research is currently being conducted to find objective methods of identifying physical pain in the brain. Researcher teams from various universities have discovered an imaging-based signature to predict pain sensitivity using functional magnetic resonance imaging (fMRI) and machine learning. 

July 26, 2016

BioIntervene Inc. to Present Clinical Results of New Class of High-Selective Adenosine AReceptor Agonists at Upcoming Pain Summit

Currently, neuropathic pain conditions affect over 15 million Americans. To help better address these painful conditions, BioIntervene Inc. is developing a novel class of highly-selective adenosine A3 receptor subtype agonist drugs for therapeutic options.

July 26, 2016

Centrexion Therapeutics to Present on Collaborative Pain Research with BioXcel at 10th Annual Pain & Migraine Therapeutics Summit

Centrexion Therapeutics has announced a collaborative agreement with BioXcel to develop and commercialize innovative chronic pain therapeutics.

July 12, 2016

Nektar Therapeutics Presents Abuse Potential Assessment of Novel Opioid Analgesic NKTR-181 at Arrowhead’s Upcoming 10th Annual Pain Summit

In the past several years, the FDA has been providing an incentive to develop abuse-deterrent products by offering differentiated labeling claims for products that meet the current required standards. Abuse potential, or the likelihood that a drug will be used for its positive psychoactive effects in nonmedical methods, was of crucial concern for Nektar Therapeutics when developing NKTR-181, a novel opioid analgesic. 

June 30, 2016

Precision Treatments for Pain Discovered by Research Team at Yale University to be Shared at 10th Annual Pain Therapeutics Summit
An estimated 100 million people in America are in need of better, more personalized treatments for pain, and a team at Yale University has proven how it should be done. Their research has shown that by using a pharmacogenomics approach which analyzes the genomes of patients, it is possible to predict and therefore reduce the likelihood of adverse drug effects. 


About Us

Our conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward.